Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:APLI)

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Business Wire April 2, 2024

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

GlobeNewswire April 2, 2024

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

GlobeNewswire March 12, 2024

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

GlobeNewswire February 13, 2024

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

Business Wire December 15, 2023

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

Business Wire November 13, 2023

Appili Therapeutics' Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

Business Wire October 25, 2023

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

Business Wire September 27, 2023

Appili Therapeutics Presents at the 10th International Tularemia Conference

Business Wire September 27, 2023
View More News ››

Opinion & Analysis (TSX:APLI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:APLI)

Appili Therapeutics Sign Definitive Agreement to be Acquired

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced...
Betteryear2 - April 2, 2024

ATI -1701

Appili was granted a pre-IND meeting with the FDA to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies and expects...
BradlTheGerman - December 17, 2023

New shareholder.

I have bought my first 75.000 shares over the last two weeks. I am going to double or triple my position over the next year. I will hold...
BradlTheGerman - December 16, 2023

FDA approval for ATI-1501

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ(TM) (ATI-1501) Metronidazole Oral Suspension Very important milestone...
mba123ccu - September 25, 2023

Seems severely under-valued. Big potential

This stock looks to have been severely punished in the past and perhaps folks are starting to look at their pipeline and realize that it&...
RJSullivan - July 17, 2023

Big bids coming in now.

What's up?
opsd1 - November 21, 2022
View more Bullboard ››

Nexera Energy Inc

Nexera Energy Inc

Nexera Energy Inc. is a Canada-based energy company with oil producing properties in southwest Texas. The Company is engaged ...
View More »